Skip to NavigationSkip to content

Jean-Pierre Garnier elected chairman of Actelion

Published on: 03/10/11

Jean-Pierre Garnier has been elected chairman of Swiss biopharmaceutical company Actelion.

He has sat on the company’s board since May and as chairman takes over from Robert Cawthorn, who had held the role since the company’s foundation in 1997.

Jean-Pierre Garnier was the first chief executive of GlaxoSmitKline, a position he held for seven years, and prior to the merger that created that company he served at SmithKline Beecham in a variety of senior roles.

Commenting on his new appointment Jean-Pierre said: "I'm very impressed with the company's track record and its position today as Europe's largest biopharmaceutical company.

“Since joining the company this spring, I have become even more convinced of Actelion's capacity to translate superior drug discovery into meaningful therapeutic solutions and long-term business success.”

Actelion has operations in more than 25 countries and its products include the hypertension brand Tracleer and Gaucher disease treatment Zavesca.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches